| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_24e76490bed88751680a5fef9bc73892 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-22 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-22 |
| filingDate |
2002-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2003-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0853dc7ae2dc8702f7870663ea4482b9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28155835d39377c1ed2e91ea9f647e8a |
| publicationDate |
2003-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-6537964-B1 |
| titleOfInvention |
Reversal of multidrug resistance in human colon carcinoma cells |
| abstract |
The present invention describes the use of fumitremorgin A, B and C and a series of diketopiperazines of Formula (I) to resensitize multidrug resistant (MDR) cancer cells to the cytotoxic effects of chemotherapeutic drugs. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005119337-A1 |
| priorityDate |
1998-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |